Drug name - Mulpleta
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7601746 | SHIONOGI INC | Compounds exhibiting thrombopoietin receptor agonism |
Sep, 2024
(1 year, 8 months from now) | |
| US8889722 | SHIONOGI INC | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jul, 2028
(5 years from now) | |
| US8530668 | SHIONOGI INC | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jan, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9427402 | SHIONOGI INC | Preparation for improving solubility of poorly soluble drug |
Sep, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
Market Authorisation Date: 31 July, 2018
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 3MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.